

JAZZ PHARMACEUTICALS INC
Form SC 13G
February 17, 2009

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 13G
(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND
AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)**

(Amendment No.)*

Jazz Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

472147107

(CUSIP Number)

December 31, 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons. Versant Affiliates Fund II-A, L.P.	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization Delaware, United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 30,724 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 30,724 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 30,724 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 0.11% (3)	
12	Type of Reporting Person* PN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; and (ii) a warrant to acquire 2,464 shares held by VAF II-A. VV II serves as the sole general partner of VAF II-A and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A; however, they disclaim beneficial ownership of the shares held by VAF II-A except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons. Versant Side Fund II, L.P.	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="checkbox"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization Delaware, United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 14,379 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 14,379 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 14,379 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 0.05% (3)	
12	Type of Reporting Person* PN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 13,247 shares held by VSF II; and (ii) a warrant to acquire 1,132 shares held by VSF II. VV II serves as the sole general partner of VSF II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VSF II; however, they disclaim beneficial ownership of the shares held by VSF II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons. Versant Venture Capital II, L.P.	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization Delaware, United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,618,289 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,618,289 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,618,289 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.62% (3)	
12	Type of Reporting Person* PN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 1,488,676 shares held by VVC II; and (ii) a warrant to acquire 129,613 shares held by VVC II. VV II serves as the sole general partner of VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VVC II; however, they disclaim beneficial ownership of the shares held by VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Versant Ventures II, LLC	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization Delaware, United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* OO	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Brian G. Atwood	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
5	Sole Voting Power 0 shares	Number of Shares Beneficially Owned by Each Reporting Person With
6	Shared Voting Power 1,683,392 shares of Common Stock (2)	
7	Sole Dispositive Power 0 shares	
8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Samuel D. Colella	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Ross A. Jaffe	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="checkbox"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons William J. Link	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
5	Sole Voting Power 0 shares	Number of Shares Beneficially Owned by Each Reporting Person With
6	Shared Voting Power 1,683,392 shares of Common Stock (2)	
7	Sole Dispositive Power 0 shares	
8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Donald B. Milder	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Rebecca B. Robertson	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Camille D. Samuels	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Bradley J. Bolzon	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="checkbox"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Charles M. Warden	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0 shares
	6	Shared Voting Power 1,683,392 shares of Common Stock (2)
	7	Sole Dispositive Power 0 shares
	8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

CUSIP No. 472147107

1	Names of Reporting Persons Barbara N. Lubash	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization United States of America	
5	Sole Voting Power 0 shares	Number of Shares Beneficially Owned by Each Reporting Person With
6	Shared Voting Power 1,683,392 shares of Common Stock (2)	
7	Sole Dispositive Power 0 shares	
8	Shared Dispositive Power 1,683,392 shares of Common Stock (2)	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,683,392 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>	
11	Percent of Class Represented by Amount in Row (9) 5.85% (3)	
12	Type of Reporting Person* IN	

(1) This Schedule 13G is filed by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (VAF II-A), Versant Side Fund II, L.P., a Delaware limited partnership (VSF II), Versant Venture Capital II, L.P., a Delaware limited partnership (VVC II), Versant Ventures II, LLC, a Delaware limited liability company (VV II), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Donald B. Milder (DBM), Rebecca B. Robertson (RBR), Camille D. Samuels (CDS), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Barbara N. Lubash (BNL) and together with VAF II-A, VSF II, VVC II, VV II, BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB and CMW, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes (i) 28,260 shares held by VAF II-A; (ii) 13,247 shares held by VSF II; (iii) 1,488,676 shares held by VVC II; (iv) warrant to acquire 2,464 shares held by VAF II-A; (v) warrant to acquire 1,132 shares held by VSF II; (vi) warrant to acquire 129,613 shares held by VVC II; and (vii) options to acquire 20,000 shares of Common Stock held directly by SDC for the benefit of VV II. VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

(3) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

Introductory Note: This Statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value \$0.0001 per share (Common Stock), of Jazz Pharmaceuticals, Inc. (the Issuer).

Item 1

(a) Name of Issuer:
 Jazz Pharmaceuticals, Inc.
 Address of Issuer's Principal Executive Offices:
 3180 Porter Drive

 Palo Alto, California

Item 2

(a) Name of Person(s) Filing:
 Versant Affiliates Fund II-A, L.P. (VAF II-A)

 Versant Side Fund II, L.P. (VSF II)

 Versant Venture Capital II, L.P. (VVC II)

 Versant Ventures II, LLC (VV II)

 Brian G. Atwood (BGA)

 Samuel D. Colella (SDC)

 Ross A. Jaffe (RAJ)

 William J. Link (WJL)

 Donald B. Milder (DBM)

 Rebecca B. Robertson (RBR)

 Camille D. Samuels (CDS)

 Bradley J. Bolzon (BJB)

 Charles M. Warden (CMW)

(b) Barbara N. Lubash (BNL)
 Address of Principal Business Office:
 c/o Versant Ventures

 3000 Sand Hill Road

 Building 4, Suite 210

 Menlo Park, California 94025

(b) Citizenship:

Entities:	VAF II-A	Delaware, United States of America
	VSF II	Delaware, United States of America

Edgar Filing: JAZZ PHARMACEUTICALS INC - Form SC 13G

	VVC II	Delaware, United States of America
	VV II	Delaware, United States of America
Individuals:	BGA	United States of America
	SDC	United States of America
	RAJ	United States of America
	WJL	United States of America
	DBM	United States of America
	RBR	United States of America
	CDS	United States of America
	BJB	United States of America
	CMW	United States of America
	BNL	United States of America

(d) Title of Class of Securities:
Common Stock

(e) CUSIP Number:
472147107

Item 3 Not applicable.

Item 4 Ownership.

The following information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2008:

Reporting Persons	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (2)
VAF II-A	30,724	0	30,734	0	30,734	30,734	0.11%
VSF II	14,379	0	14,379	0	14,379	14,379	0.05%
VVC II	1,618,289	0	1,618,289	0	1,618,289	1,618,289	5.62%
VV II	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
BGA	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
SDC	20,000	0	1,683,392	0	1,683,392	1,683,392	5.85%
RAJ	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
WJL	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
DBM	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
RBR	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
CDS	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
BJB	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
CMW	0	0	1,683,392	0	1,683,392	1,683,392	5.85%
BNL	0	0	1,683,392	0	1,683,392	1,683,392	5.85%

(1) VV II serves as the sole general partner of VAF II-A, VSF II and VVC II and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, DBM, RBR, CDS, BJB, CMW and BNL are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein.

(2) This percentage is calculated based upon 28,775,217 shares of Common Stock outstanding as of October 31, 2008, as set forth in the Issuer's most recent Form 10-Q filed with the Securities and Exchange Commission on November 14, 2008.

Item 5 Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Item 6 Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8 Identification and Classification of Members of the Group.

Not applicable.

Item 9 Notice of Dissolution of Group.

Not applicable.

Item 10 Certification.
Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2009

Versant Affiliates Fund II-A, L.P.

By: Versant Ventures II, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Side Fund II, L.P.

By: Versant Ventures II, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Venture Capital II, L.P.

By: Versant Ventures II, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Ventures II, LLC

By: /s/ Robin L. Praeger
Authorized Signer

/s/ Robin L. Praeger as attorney in fact
Brian G. Atwood

/s/ Robin L. Praeger as attorney in fact
Samuel D. Colella

/s/ Robin L. Praeger as attorney in fact
Ross A. Jaffe

/s/ Robin L. Praeger as attorney in fact
William J. Link

/s/ Robin L. Praeger as attorney in fact
Donald B. Milder

/s/ Robin L. Praeger as attorney in fact
Rebecca B. Robertson

/s/ Robin L. Praeger as attorney in fact
Camille D. Samuels

/s/ Robin L. Praeger as attorney in fact
Bradley J. Bolzon

/s/ Robin L. Praeger as attorney in fact
Charles M. Warden

/s/ Robin L. Praeger as attorney in fact
Barbara N. Lubash

Exhibit(s):

A - Joint Filing Statement

EXHIBIT A

JOINT FILING STATEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Jazz Pharmaceuticals, Inc. is filed on behalf of each of us.

Dated: February 12, 2009

Versant Affiliates Fund II-A, L.P.

By: Versant Ventures II, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Side Fund II, L.P.

By: Versant Ventures II, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Venture Capital II, L.P.

By: Versant Ventures II, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Ventures II, LLC

By: /s/ Robin L. Praeger
Authorized Signer

/s/ Robin L. Praeger as attorney in fact
Brian G. Atwood

/s/ Robin L. Praeger as attorney in fact
Samuel D. Colella

/s/ Robin L. Praeger as attorney in fact
Ross A. Jaffe

/s/ Robin L. Praeger as attorney in fact
William J. Link

/s/ Robin L. Praeger as attorney in fact
Donald B. Milder

/s/ Robin L. Praeger as attorney in fact
Rebecca B. Robertson

/s/ Robin L. Praeger as attorney in fact
Camille D. Samuels

/s/ Robin L. Praeger as attorney in fact
Bradley J. Bolzon

/s/ Robin L. Praeger as attorney in fact
Charles M. Warden

/s/ Robin L. Praeger as attorney in fact
Barbara N. Lubash
